---
title: 'Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol
  for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion
  in myelodysplastic syndromes'
date: '2024-01-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38214417/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240112170543&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: Anemia in myelodysplastic syndromes (MDS) is associated
  with poorer health-related quality of life (HRQoL) and physical function, and is
  frequently treated with transfusions. The current common practice of transfusing
  multiple red blood cells (RBC) units every 2-4 weeks may result in peaks/troughs
  in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL.
  We describe a study protocol aiming to investigate the feasibility of weekly low-dose
  RBC transfusion in ...'
disable_comments: true
---
BACKGROUND: Anemia in myelodysplastic syndromes (MDS) is associated with poorer health-related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple red blood cells (RBC) units every 2-4 weeks may result in peaks/troughs in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL. We describe a study protocol aiming to investigate the feasibility of weekly low-dose RBC transfusion in ...